JPH0359898B2 - - Google Patents
Info
- Publication number
- JPH0359898B2 JPH0359898B2 JP58022245A JP2224583A JPH0359898B2 JP H0359898 B2 JPH0359898 B2 JP H0359898B2 JP 58022245 A JP58022245 A JP 58022245A JP 2224583 A JP2224583 A JP 2224583A JP H0359898 B2 JPH0359898 B2 JP H0359898B2
- Authority
- JP
- Japan
- Prior art keywords
- carbonyl
- formula
- oxy
- compound
- methylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 208000032839 leukemia Diseases 0.000 claims abstract description 7
- 230000012010 growth Effects 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 51
- -1 (methylamino)-carbonyl Chemical group 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 239000012948 isocyanate Substances 0.000 claims description 14
- 150000002513 isocyanates Chemical class 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract description 5
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 238000002844 melting Methods 0.000 description 25
- 230000008018 melting Effects 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 8
- 239000013078 crystal Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- CMYYQTVLUJXQRH-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-tert-butylcarbamate Chemical compound CNC(=O)N(C(C)=O)OC(=O)NC(C)(C)C CMYYQTVLUJXQRH-UHFFFAOYSA-N 0.000 description 2
- LQDATRANQKTSSQ-UHFFFAOYSA-N [cyclopropanecarbonyl(propylcarbamoyl)amino] n-propylcarbamate Chemical compound CCCNC(=O)ON(C(=O)NCCC)C(=O)C1CC1 LQDATRANQKTSSQ-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- VIHDBAIWGYSTFR-UHFFFAOYSA-N n-hydroxycyclopropanecarboxamide Chemical compound ONC(=O)C1CC1 VIHDBAIWGYSTFR-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OQURWGJAWSLGQG-UHFFFAOYSA-N 1-isocyanatopropane Chemical compound CCCN=C=O OQURWGJAWSLGQG-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- ZQBSJPQCSZLHOG-UHFFFAOYSA-N [2,2-dimethylpropanoyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(=O)NC)C(=O)C(C)(C)C ZQBSJPQCSZLHOG-UHFFFAOYSA-N 0.000 description 1
- GDRBIRLKLBFXDJ-UHFFFAOYSA-N [acetyl(butylcarbamoyl)amino] n-butylcarbamate Chemical compound CCCCNC(=O)ON(C(C)=O)C(=O)NCCCC GDRBIRLKLBFXDJ-UHFFFAOYSA-N 0.000 description 1
- CYWMOWCOOYBYKZ-UHFFFAOYSA-N [acetyl(cyclohexylcarbamoyl)amino] n-cyclohexylcarbamate Chemical compound C1CCCCC1NC(=O)N(C(=O)C)OC(=O)NC1CCCCC1 CYWMOWCOOYBYKZ-UHFFFAOYSA-N 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- KFVPSAYXCYQTMK-UHFFFAOYSA-N [acetyl(phenylcarbamoyl)amino] n-phenylcarbamate Chemical compound C=1C=CC=CC=1NC(=O)N(C(=O)C)OC(=O)NC1=CC=CC=C1 KFVPSAYXCYQTMK-UHFFFAOYSA-N 0.000 description 1
- FYYNYTLWTNFHAS-UHFFFAOYSA-N [acetyl(propan-2-ylcarbamoyl)amino] n-propan-2-ylcarbamate Chemical compound CC(C)NC(=O)ON(C(C)=O)C(=O)NC(C)C FYYNYTLWTNFHAS-UHFFFAOYSA-N 0.000 description 1
- SDVNEYFNWCZEDS-UHFFFAOYSA-N [acetyl(propylcarbamoyl)amino] n-propylcarbamate Chemical compound CCCNC(=O)ON(C(C)=O)C(=O)NCCC SDVNEYFNWCZEDS-UHFFFAOYSA-N 0.000 description 1
- LSNBVLYXRZAHAC-UHFFFAOYSA-N [acetyl(tert-butylcarbamoyl)amino] n-tert-butylcarbamate Chemical compound CC(C)(C)NC(=O)N(C(=O)C)OC(=O)NC(C)(C)C LSNBVLYXRZAHAC-UHFFFAOYSA-N 0.000 description 1
- KUUQWZJOSIGJFP-UHFFFAOYSA-N [acetyl-[(3-methylphenyl)carbamoyl]amino] n-(3-methylphenyl)carbamate Chemical compound C=1C=CC(C)=CC=1NC(=O)N(C(=O)C)OC(=O)NC1=CC=CC(C)=C1 KUUQWZJOSIGJFP-UHFFFAOYSA-N 0.000 description 1
- TUZYCYGFIFHVRI-UHFFFAOYSA-N [acetyl-[(4-methylphenyl)carbamoyl]amino] n-(4-methylphenyl)carbamate Chemical compound C=1C=C(C)C=CC=1NC(=O)N(C(=O)C)OC(=O)NC1=CC=C(C)C=C1 TUZYCYGFIFHVRI-UHFFFAOYSA-N 0.000 description 1
- CDEPGIYPAJXMAG-UHFFFAOYSA-N [benzoyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(=O)NC)C(=O)C1=CC=CC=C1 CDEPGIYPAJXMAG-UHFFFAOYSA-N 0.000 description 1
- JEDKOPDVYJICRO-UHFFFAOYSA-N [benzoyl(phenylcarbamoyl)amino] n-phenylcarbamate Chemical compound C=1C=CC=CC=1NC(=O)N(C(=O)C=1C=CC=CC=1)OC(=O)NC1=CC=CC=C1 JEDKOPDVYJICRO-UHFFFAOYSA-N 0.000 description 1
- BSFZTEHBSPCPTF-UHFFFAOYSA-N [benzoyl(propan-2-ylcarbamoyl)amino] n-propan-2-ylcarbamate Chemical compound CC(C)NC(=O)ON(C(=O)NC(C)C)C(=O)C1=CC=CC=C1 BSFZTEHBSPCPTF-UHFFFAOYSA-N 0.000 description 1
- KZQUDIJFQJZKJM-UHFFFAOYSA-N [benzoyl(propylcarbamoyl)amino] n-propylcarbamate Chemical compound CCCNC(=O)ON(C(=O)NCCC)C(=O)C1=CC=CC=C1 KZQUDIJFQJZKJM-UHFFFAOYSA-N 0.000 description 1
- MBMVEHLDUZXWPP-UHFFFAOYSA-N [benzoyl(tert-butylcarbamoyl)amino] n-tert-butylcarbamate Chemical compound CC(C)(C)NC(=O)ON(C(=O)NC(C)(C)C)C(=O)C1=CC=CC=C1 MBMVEHLDUZXWPP-UHFFFAOYSA-N 0.000 description 1
- WLBFTDQYYWFOHM-UHFFFAOYSA-N [cyclohexylcarbamoyl(cyclopropanecarbonyl)amino] n-cyclohexylcarbamate Chemical compound C1CCCCC1NC(=O)N(C(=O)C1CC1)OC(=O)NC1CCCCC1 WLBFTDQYYWFOHM-UHFFFAOYSA-N 0.000 description 1
- LZWPPKWORJRBBP-UHFFFAOYSA-N [cyclopropanecarbonyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(=O)NC)C(=O)C1CC1 LZWPPKWORJRBBP-UHFFFAOYSA-N 0.000 description 1
- PLWGXZYSZBUAPR-UHFFFAOYSA-N [cyclopropanecarbonyl(phenylcarbamoyl)amino] n-phenylcarbamate Chemical compound C=1C=CC=CC=1NC(=O)N(C(=O)C1CC1)OC(=O)NC1=CC=CC=C1 PLWGXZYSZBUAPR-UHFFFAOYSA-N 0.000 description 1
- GPFXTBLPSNPIHF-UHFFFAOYSA-N [cyclopropanecarbonyl(propan-2-ylcarbamoyl)amino] n-propan-2-ylcarbamate Chemical compound CC(C)NC(=O)ON(C(=O)NC(C)C)C(=O)C1CC1 GPFXTBLPSNPIHF-UHFFFAOYSA-N 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- IYEBVKCNBIGUJR-UHFFFAOYSA-N [methylcarbamoyl(propanoyl)amino] n-methylcarbamate Chemical compound CCC(=O)N(C(=O)NC)OC(=O)NC IYEBVKCNBIGUJR-UHFFFAOYSA-N 0.000 description 1
- NWAVDZPATQKPSN-UHFFFAOYSA-N [tert-butylcarbamoyl(cyclopropanecarbonyl)amino] n-tert-butylcarbamate Chemical compound CC(C)(C)NC(=O)ON(C(=O)NC(C)(C)C)C(=O)C1CC1 NWAVDZPATQKPSN-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000012975 dibutyltin dilaurate Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- LDDOSDVZPSGLFZ-UHFFFAOYSA-N ethyl cyclopropanecarboxylate Chemical compound CCOC(=O)C1CC1 LDDOSDVZPSGLFZ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- ATDOYFPHCIRHKH-UHFFFAOYSA-N n-hydroxy-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NO ATDOYFPHCIRHKH-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/64—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
- Polyamides (AREA)
Description
æ¬çºæã¯åŒ
ïŒåŒäžR1ïŒR2åã³R3ã¯åã
ç¬ç«ããŠæ°ŽçŽ ãäœ
çŽã¢ã«ãã«ãã·ã¯ãã¢ã«ãã«ãããšãã«åã¯äœçŽ
ã¢ã«ãã«çœ®æããšãã«ãè¡šãããã¯ã«ã«ããã«
çŽã¢ã«ãã«ãã·ã¯ãã¢ã«ãã«ãããšãã«åã¯äœçŽ
ã¢ã«ãã«çœ®æããšãã«ãè¡šãããã¯ã«ã«ããã«
ãåŒãåã¯ã¹ã«ããã«âSO2âã§ããïŒ
ã«å¯Ÿå¿ããæ°èŠãªææ©ååç©çŸ€ã«é¢ããã
æ¬æ现æžã§ãäœçŽã¢ã«ãã«ããšããèªã¯ïŒãã
çŽïŒåã®ççŽ ååã®èèªæçŽéåã¯åæéã®åºã
äŸãã°ã¡ãã«ããšãã«ãã€ãœãããã«ã第ïŒãã
ã«ãªã©ãããããã·ã¯ãã¢ã«ãã«ããšããèªã¯ïŒ
ãçŽïŒåã®ççŽ ååã®é£œååç°åŒçåæ°ŽçŽ åºãäŸ
ãã°ã·ã¯ããããã«ãã·ã¯ãããã·ã«ãªã©ãã
ãã æ¬çºæã®å¥œãŸããååç©ã¯R1ïŒR2åã³R3ã
åã äœçŽã¢ã«ãã«ã§ïŒžãã«ã«ããã«åã¯ã¹ã«ãã
ã«ã§ããåŒã®ååç©ã§ãããç¹ã«å¥œãŸããã®ã¯
R1ïŒR2ïŒR3ãåã ã¡ãã«ã§ïŒžãã«ã«ããã«åã¯
ã¹ã«ããã«ã§ãããç¹ã«å¥œãŸããã®ã¯R1ïŒR2å
ã³R3ãåã ã¡ãã«ã§ïŒžãã«ã«ããã«ã§ããåå
ç©ã§ããã æ¬çºæã®ååç©ã¯åºä¹³é¡ã«æŒããŠãã©çŽ°èã®çŽ°
èçé·ãæå¶ããã®ã«æå¹ã§ããããšãããã€
ããæŽã«P388çœè¡ç åã¯MXâïŒçã«ããã€ãåº
ä¹³é¡ã«æŒãŠãããããæå¶ããã®ã«æå¹ã§ããã
ãšãããã€ãã æ¬çºæã¯R1ãR2åã³R3ã¯åã ç¬ç«ã«ïŒãïŒå
ã®ççŽ ååã®ã¢ã«ãã«ã§ããããã«ã«ããã«ã§
ããåŒïŒïŒã®æŽ»æ§ååç©ïŒïŒåã¯ãã以äžïŒã®
æå¹éãšè£œè¬æ äœãšã®çµåããå«æããããã©çŽ°
èãP388çœè¡ç åã¯MXâïŒçã®æé·ãæå¶ãã
ã®ã«é©ããçµæç©ã«é¢ããã æ¬çºæã®ååç©ã¯æ¬¡ã®æ¹æ³ã§å®¹æã«è£œé åºæ¥
ãã (A) ãã«ã«ããã«ã§R1ïŒR2ïŒR3ãåã«äžãã
æå³ãæããR2ãšR3ãåã眮æåºã§ããåŒ
ã®ååç©ã¯åŒ ã®R1â眮æâã¢ã·ã«ãããããµã é žã眮æåº
ãåŒã®R2ãšR3ã®åã ã«ã€ããŠéžæãããã
ããªãã®ã§ãã眮æã€ãœã·ã¢ããŒããšåå¿ãã
ãŠè£œé ãããã ãã®åå¿ã§ã¯è¯å¥œãªçµæã¯çœ®æã€ãœã·ã¢ããŒ
ããR1â眮æã¢ã·ã«ãããããµã é žã®ã¢ã«æ¿
床ã®ïŒåã®ã¢ã«æ¿åºŠã§ååšãããšãã«åŸãã
ããããã䜿çšåå¿äœã®éã¯èšççã§ã¯ãªãã
æãŸããçæç©ã®ãããã®ã¯åå¿äœãã©ããªå²
åã§çšãããããšãã«ãåŸãããã§ãããã åå¿äœãå¡©åã¡ãã¬ã³åã¯ããã©ããããã©
ã³ãªã©ã®äžæŽ»æ§ææ©æº¶åªäžã§ãžããã«é«ãžã©ãŠ
ã¬ãŒãåã¯ããªãšãã«ã¢ãã³ãªã©ã®å°éã®æŽ»æ§
åå€ã®ååšäžã§äºã«æ¥è§Šããããåå¿æ··åç©ã
çŽå®€æž©ã§å€§æ°å§äžã§å®è³ªçåå¿å®äºã確å®ã«
ãããããŠææçæç©ãåŸãã«ååãªæéæ¹æ
ããã®ãéœåè¯ããããé«ãå§ååã¯ããäœã
枩床ã䜿çšããåã¯åå¿ãå®äºãããããã«é«
å§ãçšããã®ãå¿ èŠãããããªãã åå¿ã®å®çµã«æŒãŠã溶åªãèžçºããéãåã¯
åŸæãªã©ã®æ £çšæè¡ã§åå¿æ··åç©ããé€å»ã
ããçæç©ã®ç²Ÿè£œã¯ãã®æè¡ã§è¯ãç¥ãããæ
é äŸãã°åçµæ¶ã§è¡ãã (B) ãã«ã«ããã«ã§R1ïŒR2åã³R3ãåã«äžã
ãæå³ãæããR2ãšR3ãç°ãªãéšåãè¡šãã
åŒã®ååç©ã¯å®è³ªçã«ïŒæ®µéæé ãçšããŠè£œ
é ãããã第ïŒæ®µéã§ã¯åŒã§è¡šããããã¢ã·
ã«ãããããµã é žããããçã¢ã«éã®ãåã«
R2ã«ã€ãå®çŸ©ããéšåã®äžã€ã§çœ®æãããã€
ãœã·ã¢ããŒããšåå¿ãããããã®åå¿ã®å®äºã«
æŒãŠãçæç©ããããçã¢ã«éã®ãR3ã«ã€ã
åã«å®çŸ©ããéšåã®äžã€ã§çœ®æãããã€ãœã·ã¢
ããŒããšåå¿ããææåŒååç©ãæ®ãã 䜿çšããåå¿äœã®æ£ç¢ºãªå²åã¯èšççã§ã¯ãª
ããããã®ïŒæ®µæ¹æ³ã®å段éã¯æ¬è³ªçã«çãã
å²åãè¡šããéã®åå¿äœãæ¶è²»ãããããŠãã®
æ§ãªéã®äœ¿çšã奜ãŸããã äžã®åå¿ãåã«äžèš(A)ã§èšãããšå®è³ªçã«å
ãåå¿æ¡ä»¶ã䜿çšããŠå®æœããã®ãéœåè¯ãã
ãããã®ååç©ã¯äžã®(A)ã«è¿°ã¹ãæ £çšæè¡ãçš
ããŠåååã³ç²Ÿè£œãè¡ãããã (C) ãã¹ã«ããã«ã§R1ïŒR2åã³R3ãåã«äžã
ãããæå³ãæããR2ãšãšR3ãåã眮æåºã§
ããåŒã®ååç©ã¯äžã®(A)ãšå®è³ªçã«åãæ¹æ³
ã§ãŸãå®è³ªçã«åãæ¡ä»¶åã³å²åã§è£œé ãã
ããåŒ ã®ææã®ïŒ®âããããã·âR1â眮æã¹ã«ãã¢
ããã¯çœ®æåºããåŒã®R2ãšR3ã®åã ã«å¯Ÿã
ãŠéžã°ãããã®ã§ãããããªã€ãœã·ã¢ããŒããš
åå¿ãããããã§çœ®æã€ãœã·ã¢ããŒãã®ã¢ã«æ¿
床ã¯åŒã®ïŒ®âããããã·âR1â眮æã¹ã«ã
ã¢ããã®ãã®ã®çŽïŒåã§ããã (D) åæ§ã«ïŒžãã¹ã«ããã«ã§R1ïŒR2åã³R3ãå
ã«äžããæå³ãæããR2ãšR3ãç°ãªãéšåã
è¡šããåŒã®ååç©ã¯äžã®(B)ã«èšãããã®ãšå®
質çã«åãæ¹æ³ã§ããããŠå®è³ªçã«åãæ¡ä»¶å
ã³å²åã§è£œé ããããåŒã®æãâãããã
ã·âR1â眮æã¹ã«ãã¢ããã¯R2ã«ã€ãåã«å®
矩ããéšåã®äžã€ã§çœ®æãããã€ãœã·ã¢ããŒã
ã®çŽçã¢ã«éãšåå¿ããããåå¿å®äºã«æŒãŠç
ããçæç©ãR3ã«ã€ãåã«å®çŸ©ããéšåã®äž
ã€ã§çœ®æãããçŽçã¢ã«éã®ã€ãœã·ã¢ããŒããš
åå¿ãããåŒã®æãååç©ãæ®ãã æ¬çºæååç©ã®è£œé ã«åºçºç©ãšããŠçšãããã
ååç©ã¯åœæè¡ã§ç¥ãããŠããã 次ã®å®æœäŸã¯æ¬çºæã説æããæ段ãšããŠèšã
ããããããã¯å¥œãŸããæ æ§ã®äŸã§ãã€ãŠæ¬çºæ
ãå¶éãããã®ãšããŠæå³ãããŠããªãã å®æœäŸ ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ã
ã ã¢ã»ããããããµã é žïŒ7.5ïœïŒãã¡ãã«ã€ãœã·
ã¢ããŒãïŒ12.0ã°ã©ã ïŒã80ããªãªããã«ïŒmlïŒ
ã®å¡©åã¡ãã¬ã³ãåã³çŽïŒæ»Žã®ããªãšãã«ã¢ãã³
ã®æ··åç©ã溶液ãåŸãããã«çŽïŒæéäžç·ã«æ¹æ
ããã溶液ã宀枩ã§äžå€æŸçœ®ãããã®åŸæº¶åªãç
空äžã«é€å»ããæ®æž£ãæ®ãããæ®æž£ãå¡©åã¡ãã¬
ã³ããåçµæ¶ããçœè²çµæ¶ãšããŠæãâïŒïŒã¡ã
ã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡ãã«ã¢ããïŒ
ã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãããæ®ãããè
ç¹ïŒm.p.ïŒ121ãã123.5âã å®æœäŸ ïŒ ïŒ®âïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒãš
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ã
ã ã¢ã»ããããããµã é žïŒ7.5ïœïŒããšãã«ã€ãœã·
ã¢ããŒãïŒ16.0ïœïŒåã³çŽïŒæ»Žã®ããªãšãã«ã¢ã
ã³ãçŽ50mlã®å¡©åã¡ãã¬ã³äžã§çŽ48æéæ¹æã
ããæ··åç©ã次ã«ç空äžã«æ¿çž®ãæ®æž£ãæ®ããã
ãã®æ®æž£ãå¡©åã¡ãã¬ã³ãšãããµã³ã®æº¶æ¶²ããïŒ
ååçµæ¶ããã次ã«å°éã®å¡©åã¡ãã¬ã³ããåçµ
æ¶ãããããã«ãšã³ããã®æçµã®åçµæ¶ã§çœè²çµ
æ¶ãšããŠæãâïŒïŒãšãã«ã¢ããïŒâã«ã«ããã«ïŒ
ââïŒïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒ
ã¢ã»ãã¢ãããçæãããèç¹84â86âã å®æœäŸ ïŒ ïŒ®âïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«
ã«ããã«ïŒââïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒ
ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãã ã¢ã»ããããããµã é žïŒ7.5ïœïŒã第ïŒããã«ã€
ãœã·ã¢ããŒãïŒ22ïœïŒåã³æ°æ»Žã®ããªãšãã«ã¢ã
ã³ã80mlã®å¡©åã¡ãã¬ã³äžã§çŽ48æéæ¹æããã
æ¹æåŸã溶åªãç空äžã«é€å»ããŠæ®æž£ãæ®ããã
ããå¡©åã¡ãã¬ã³åã³ãããµã³ãå«ã溶液ããå
çµæ¶ããããå¡©åã¡ãã¬ã³ããã®æ¬¡ã®åçµæ¶ã§æ
ãâïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«
ã«ããã«ïŒââïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒ
ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãããæ®
ã€ããèç¹111ãã113âã å®æœäŸ ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒããããªã³
ã¢ãã ããããªãããããµã é žïŒ4.5ïœïŒãã¡ãã«ã€ãœ
ã·ã¢ããŒãïŒ6.0ïœïŒåã³æ°æ»Žã®ããªãšãã«ã¢ã
ã³ãçŽïŒæéçŽ50mlã®å¡©åã¡ãã¬ã³äžã§æ¹æã
ããçãã溶液ã宀枩ã§çŽ48æéæŸçœ®ãããã®åŸ
溶åªãèžçºãããŠé€ãæ®æž£ãæ®ãããæ®æž£ãå¡©å
ã¡ãã¬ã³ãšãããµã³ã®æ··åç©ããåçµæ¶ããæã
âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡ã
ã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒããããªã³ã¢ã
ããçœè²çµæ¶ãšããŠæ®ã€ããèç¹90.5ã92.5âã å®æœäŸ ïŒ ïŒ®âïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒãš
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒããããªã³
ã¢ãã ããããªãããããµã é žïŒ4.5ïœïŒããšãã«ã€ãœ
ã·ã¢ããŒãïŒ8.0ïœïŒåã³æ°æ»Žã®ããªãšãã«ã¢ã
ã³ã100mlã®å¡©åã¡ãã¬ã³ã«å ãã宀枩ã§çŽ12æ
éæŸçœ®ããã溶åªã次ã«ç空äžã§é€ããæ®æž£ãæ®
ãããããå¡©åã¡ãã¬ã³ãšãããµã³ã®æº¶æ¶²ããå
çµæ¶ããçœè²çµæ¶ãšããŠæãâïŒïŒãšãã«ã¢ã
ãïŒã«ã«ããã«ïŒââïŒïŒïŒãšãã«ã¢ããïŒã«ã«ã
ãã«ïŒãªãã·ïŒããããªã³ã¢ãããæ®ãããèç¹
104âã106âã å®æœäŸ ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·âïŒïŒïŒâãž
ã¡ãã«ïŒããããªã³ã¢ãã ïŒïŒïŒïŒâãžã¡ãã«ïŒããããªãããããµã é ž
ïŒ5.9ïœïŒãã¡ãã«ã€ãœã·ã¢ããŒãïŒ6.5ïœïŒåã³æ°
滎ã®ããªãšãã«ã¢ãã³ãçŽ50mlã®å¡©åã¡ãã¬ã³äž
ã§çŽ48æéæ¹æããããã®æ··åç©ã次ã«ç空äžã§
æ¿çž®ããç¡è²ã®æ²¹ç¶æ®æž£ãæ®ããããã®æ²¹ããã
ãµã³ãšããç ããšç²çæ§ã®åºäœãæ®ãããããå¡©
åã¡ãã¬ã³ãšãããµã³ã®æº¶æ¶²ããåçµæ¶ãããã
ãã®åŸã®æå°éã®å¡©åã¡ãã¬ã³åã³ãã«ãšã³ãã
ã®åçµæ¶ã§çœè²çµæ¶ãšããŠæãâïŒïŒã¡ãã«ã¢ã
ãïŒâã«ã«ããã«ïŒââïŒïŒïŒã¡ãã«ã¢ããïŒã«ã«
ããã«ïŒãªãã·ïŒïŒïŒïŒïŒâãžã¡ãã«ïŒããããª
ã³ã¢ãããæ®ã€ããèç¹117ãã119âïŒçŽ116âã
ããããã®çŒçµããïŒã äžèšã®æé ãšå®è³ªçã«åæé ã§é©åœãªçœ®æã¢ã·
ã«ãããããµã é žãé©åœãªã€ãœã·ã¢ããŒããšåå¿
ãããããšã«ãã次ã®ååç©ãã€ãã€ãã å®æœäŸïŒïŒ âïŒïŒã·ã¯ãããã·ã«ã¢ããïŒã«ã«
ããã«ïŒââïŒïŒïŒã·ã¯ãããã·ã«ã¢ããïŒã«ã«
ããã«ïŒãªãã·ïŒã¢ã»ãã¢ããèç¹109ãã112
âã å®æœäŸïŒïŒ âïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢ããïŒ
ã«ã«ããã«ïŒââïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢ã
ãïŒã«ã«ããã«ïŒãªãã·ã¢ã»ãã¢ããèç¹65ã
ã68âã å®æœäŸïŒïŒ âïŒïŒãããã«ã¢ããïŒã«ã«ãã
ã«ïŒââïŒïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒãª
ãã·ïŒã¢ã»ãã¢ãããèç¹50ãã53âã å®æœäŸ10ïŒ ïŒ®âïŒïŒããšãã«ã¢ããïŒã«ã«ãã
ã«ïŒââïŒïŒïŒããšãã«ã¢ããïŒã«ã«ããã«ïŒãª
ãã·ïŒã¢ã»ãã¢ãããèç¹134ãã136âã å®æœäŸ11ïŒ ïŒ®âïŒïŒïŒïŒâã¡ãã«ããšãã«ïŒã¢ã
ãïŒã«ã«ããã«ïŒââïŒïŒïŒïŒïŒâã¡ãã«ããšã
ã«ïŒã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ã
ã å®æœäŸ12ïŒ ïŒ®âïŒïŒïŒïŒâã¡ãã«ããšãã«ïŒã¢ã
ãïŒã«ã«ããã«ïŒââïŒïŒïŒïŒïŒâã¡ãã«ããšã
ã«ïŒã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ã
ããèç¹140ãã142âã å®æœäŸ13ïŒ ïŒ®âïŒïŒããã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒããã«ã¢ããïŒâã«ã«ããã«ïŒãªã
ã·ïŒã¢ã»ãã¢ãã å®æœäŸ14ïŒ ïŒ®âïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢ããïŒ
ã«ã«ããã«ïŒââïŒïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢
ããïŒã«ã«ããã«ïŒãªãã·ïŒãã³ãºã¢ãã å®æœäŸ15ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒã¡ãã«ã¢ããïŒâã«ã«ããã«ïŒãªã
ã·ïŒãã³ãºã¢ãããèç¹131ãã133âã å®æœäŸ16ïŒ ïŒ®âïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒ
ãã³ãºã¢ãããèç¹154ãã155âã å®æœäŸ17ïŒ ïŒ®âïŒïŒãããã«ã¢ããïŒã«ã«ãã
ã«ïŒââïŒïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒãª
ãã·ïŒãã³ãºã¢ããèç¹66ãã69âã å®æœäŸ18ïŒ ïŒ®âïŒïŒããã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒããã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒ
ãã³ãºã¢ããèç¹42ã43âã å®æœäŸ19ïŒ ïŒ®âïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒ
ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒïŒïŒïŒïŒâãžã¡
ãã«ãšãã«ïŒã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã
ã³ãºã¢ããèç¹133ãã134âã å®æœäŸ20ïŒ ïŒ®âïŒïŒããšãã«ã¢ããïŒã«ã«ãã
ã«ïŒââïŒïŒïŒããšãã«ã¢ããïŒã«ã«ããã«ïŒãª
ãã·ïŒãã³ãºã¢ãã å®æœäŸ21ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒ
ã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãã (a) âïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ã
ãïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãã ã¢ã»ããããããµã é žïŒ7.5ïœïŒã第ïŒããã«ã€
ãœã·ã¢ããŒãïŒ10.0ïœïŒåã³æ°æ»Žã®ããªãšãã«ã¢
ãã³ã宀枩ã§çŽ200mlã®å¡©åã¡ãã¬ã³äžã§ïŒæé
æ¹æããããã®æéã®åŸãåå¿ããã®äžæº¶åºäœã
æ¿ŸéããŠéãææçæç©ã§ããããšã決å®ããã
ã液ãç空äžã«æ¿çž®ããŠæ®æž£ãæ®ããããããã«
ãšã³ããåçµæ¶ãããè¿œå éã®ææã®ïŒ®â
ïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«ã«ãã
ã«ïŒãªãã·ïŒã¢ã»ãã¢ãããæ®ããã (b) âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââ
ïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«ã«
ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãã âïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«
ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ããïŒ8.7ïœïŒãã¡ã
ã«ã€ãœã·ã¢ããŒãïŒ3.2ïœïŒåã³æ°æ»Žã®ããªãšã
ã«ã¢ãã³ã宀枩ã§150mlã®å¡©åã¡ãã¬ã³äžã§çŽ12
æéæ¹æããã溶åªã次ã«ç空äžã§é€ãæ²¹ç¶æ®æž£
ãæ®ãããããç±ããã«ãšã³äžã«æº¶è§£ãããå·åŽ
ãããšçœè²ã®çµæ¶ç©è³ªãåé¢ããæ¿Ÿéã§éããã
çœè²ã®çµæ¶ããã«ãšã³ããåçµæ¶ãããæ®æž£ãæ®
ãããããçŽ50mlã®æ°ŽãšçŽïŒæéæ··åãããæ··å
ç©ã次ã«æ¿Ÿéãã次ã«äžæº¶ç©ãç空也ç¥ããæã
âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒïŒïŒ
ïŒ
ïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«ã«ããã«ïŒãªã
ã·ïŒã¢ã»ãã¢ãããèç¹142ã144âãæ®ããã å®æœäŸ 22 âïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒââ
ïŒïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã·
ã¯ããããã³ã«ã«ãããµãã (a) âããããã·ã·ã¯ããããã³ã«ã«ãããµã
ãã®è£œé çŽ500mlã®ã¡ã¿ããŒã«äžã®çŽ1.3ã¢ã«ã®ãããã
ã·ã«ã¢ãã³å¡©é žå¡©ã®æº¶æ¶²ã調補ããŠå·åŽãããã
ãã«çŽ2.0ã¢ã«ã®æ°Žé žåã«ãªãŠã ãå«æãã300ml
ã®ã¡ã¿ããŒã«æº¶æ¶²ãå ãããçŽïŒååŸããšãã«ã·
ã¯ããããã³ã«ã«ããã·ã¬ãŒãïŒ0.66ã¢ã«ïŒãå
ããããã®åå¿æ··åç©ãçŽ10ååŸã«æ¿ŸéããŠãæ®
枣ãæ®ãããããã¡ã¿ããŒã«ã§æŽã€ãåŸã«é žæ§ã«
ãããé žæ§ã«ããæ··åç©ããéããã液ãæ¿çž®ã
ãŠåºäœãæ®ãããåºäœãé ¢é žãšãã«ããåçµæ¶ã
ããçœè²åºäœãæ®ããâããããã·ã·ã¯ããã
ãã³ã«ã«ãããµããã§ããããšã決å®ãããèç¹
117ã119â (b) âïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒââ
ïŒïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã·
ã¯ããããã³ã«ã«ãããµãã âããããã·ã·ã¯ããããã³ã«ã«ãããµãã
ïŒ5.0ïœïŒãïœâãããã«ã€ãœã·ã¢ããŒãïŒ9.3ïœïŒ
åã³ïŒæ»Žã®ããªãšãã«ã¢ãã³ã宀枩ã§çŽ100mlã®
å¡©åã¡ãã¬ã³äžã§çŽ12æéæ¹æãããåå¿æ··åç©
ã次ã«æ¿çž®ããŠæ²¹ç¶æ®çç©ãæ®ããããã²ã€ãã
ãšçµæ¶åããããã®åºäœã次ã«ã·ã¯ããããµã³ãš
ã€ãœãããããŒã«ã®æ··åç©ããåçµæ¶ãããããŠ
也ç¥ãããã也ç¥ãããšæãâïŒïŒãããã«ã¢ã
ãïŒã«ã«ããã«ïŒââïŒïŒïŒãããã«ã¢ããïŒã«ã«
ããã«ïŒãªãã·ïŒã·ã¯ããããã³ã«ã«ãããµãã
ãçœè²åºäœãšããŠåŸããããèç¹76ãã78â å®è³ªçã«åãæé ã䜿ã€ãŠæ¬¡ã®ååç©ãã€ãã€
ãã å®æœäŸ 23 âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã·ã¯ããã
ãã³ã«ã«ãããµãããèç¹109ãã111â å®æœäŸ24 âïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒâ
âïŒïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒ
ã·ã¯ããããã³ã«ã«ãããµããèç¹120ã122
âã å®æœäŸ25 âïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢ããïŒ
ã«ã«ããã«ïŒââïŒïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢
ããïŒã«ã«ããã«ïŒãªãã·ïŒã·ã¯ããããã³ã«
ã«ãããµããèç¹99ãã101âã å®æœäŸ26 âïŒïŒããã«ã¢ããïŒã«ã«ããã«ïŒâ
âïŒïŒïŒããã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒ
ã·ã¯ããããã³ã«ã«ãããµãããèç¹48ãã49
âã å®æœäŸ27 âïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢
ããïŒã«ã«ããã«ïŒââïŒïŒïŒïŒïŒïŒïŒâãžã¡ã
ã«ãšãã«ïŒã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã·ã¯
ããããã³ã«ã«ãããµããã å®æœäŸ28 âïŒïŒããšãã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒããšãã«ã¢ããïŒã«ã«ããã«ïŒãªã
ã·ïŒã·ã¯ããããã³ã«ã«ãããµãããèç¹140
ã142âã å®æœäŸ29 âïŒïŒã·ã¯ãããã·ã«ã¢ããïŒã«ã«ã
ãã«ïŒââïŒïŒïŒã·ã¯ãããã·ã«ã¢ããïŒã«ã«ã
ãã«ïŒãªãã·ïŒã·ã¯ããããã³ã«ã«ãããµã
ããèç¹122ãã124âã å®æœäŸ 30 âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¡ã¿ã³ã¹ã«
ãã¢ãã (a) âããããã·ã¡ã¿ã³ã¹ã«ãã¢ããã®è£œé ãããªãŠã ã¡ããã·ãã®æº¶æ¶²ã23ïœã®ãããªãŠ
ã ã300mlã®ã¡ã¿ããŒã«äžã«æº¶ãããŠã€ãã€ãã
ãã®æº¶æ¶²ã300mlã®ã¡ã¿ããŒã«äžã®69ïœã®ããã
ãã·ã«ã¢ãã³å¡©é žå¡©ã«ïŒå·åŽããªããïŒå ãã次
ã«æ¿Ÿéãããã液ãçŽ15âã«å·ãããã¡ã¿ã³ã¹ã«
ããã«ã¯ãã©ã€ãïŒ19.3mlïŒãçŽ48æéåŸå ãã
åå¿æ··åç©ããéããã液ãæ¿çž®ããŠæ®æž£ãæ®ã
ããæ®æž£ããžãšãã«ãšãŒãã«ã§ïŒåæœåºããäžç·
ã«ãããšãŒãã«æœåºç©ãæ¿çž®ããŠæããé»è²ã®ç²
æ§ã®æ²¹ãæ®ãããçœè²ã®åºäœãã²ã€ãããåŸã«åœ¢
æãããããã¯æãâããããã·ã¡ã¿ã³ã¹ã«ã
ã¢ãããšäžèŽããèµ€å€åžåãæããŠããã (b) âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââ
ïŒïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¡ã¿
ã³ã¹ã«ãã¢ãã âããããã·ã¡ã¿ã³ã¹ã«ãã¢ããïŒ8.0ïœïŒã
ã¡ãã«ã€ãœã·ã¢ããŒãïŒ9.4mlïŒåã³çŽïŒæ»Žã®ã
ãªãšãã«ã¢ãã³ãçŽ80mlã®å¡©åã¡ãã¬ã³äžã§æ¥è§Š
ãããåå¿ãé²è¡ããã«åŸãçœè²åºäœã圢æã
ãã次ã«ååãããåºäœãã€ãœãããããŒã«ãã
åçµæ¶ããæãâïŒïŒã¡ãã«ã¢ããïŒã«ã«ãã
ã«ïŒââïŒïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒãªã
ã·ïŒã¡ã¿ã³ã¹ã«ãã¢ãããæ®ãããèç¹131ãã
132â æ¬è³ªçã«å®æœäŸ30ãšåãæé ã«åŸã€ãŠæ¬¡ã®åå
ç©ãã€ãã€ãã å®æœäŸ 31 âïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒãš
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¡ã¿ã³ã¹ã«
ãã¢ãã åŒã®ååç©ã®ç©æ§ã¯è¡šïŒã«èšãããã
çŽïŒåã®ççŽ ååã®èèªæçŽéåã¯åæéã®åºã
äŸãã°ã¡ãã«ããšãã«ãã€ãœãããã«ã第ïŒãã
ã«ãªã©ãããããã·ã¯ãã¢ã«ãã«ããšããèªã¯ïŒ
ãçŽïŒåã®ççŽ ååã®é£œååç°åŒçåæ°ŽçŽ åºãäŸ
ãã°ã·ã¯ããããã«ãã·ã¯ãããã·ã«ãªã©ãã
ãã æ¬çºæã®å¥œãŸããååç©ã¯R1ïŒR2åã³R3ã
åã äœçŽã¢ã«ãã«ã§ïŒžãã«ã«ããã«åã¯ã¹ã«ãã
ã«ã§ããåŒã®ååç©ã§ãããç¹ã«å¥œãŸããã®ã¯
R1ïŒR2ïŒR3ãåã ã¡ãã«ã§ïŒžãã«ã«ããã«åã¯
ã¹ã«ããã«ã§ãããç¹ã«å¥œãŸããã®ã¯R1ïŒR2å
ã³R3ãåã ã¡ãã«ã§ïŒžãã«ã«ããã«ã§ããåå
ç©ã§ããã æ¬çºæã®ååç©ã¯åºä¹³é¡ã«æŒããŠãã©çŽ°èã®çŽ°
èçé·ãæå¶ããã®ã«æå¹ã§ããããšãããã€
ããæŽã«P388çœè¡ç åã¯MXâïŒçã«ããã€ãåº
ä¹³é¡ã«æŒãŠãããããæå¶ããã®ã«æå¹ã§ããã
ãšãããã€ãã æ¬çºæã¯R1ãR2åã³R3ã¯åã ç¬ç«ã«ïŒãïŒå
ã®ççŽ ååã®ã¢ã«ãã«ã§ããããã«ã«ããã«ã§
ããåŒïŒïŒã®æŽ»æ§ååç©ïŒïŒåã¯ãã以äžïŒã®
æå¹éãšè£œè¬æ äœãšã®çµåããå«æããããã©çŽ°
èãP388çœè¡ç åã¯MXâïŒçã®æé·ãæå¶ãã
ã®ã«é©ããçµæç©ã«é¢ããã æ¬çºæã®ååç©ã¯æ¬¡ã®æ¹æ³ã§å®¹æã«è£œé åºæ¥
ãã (A) ãã«ã«ããã«ã§R1ïŒR2ïŒR3ãåã«äžãã
æå³ãæããR2ãšR3ãåã眮æåºã§ããåŒ
ã®ååç©ã¯åŒ ã®R1â眮æâã¢ã·ã«ãããããµã é žã眮æåº
ãåŒã®R2ãšR3ã®åã ã«ã€ããŠéžæãããã
ããªãã®ã§ãã眮æã€ãœã·ã¢ããŒããšåå¿ãã
ãŠè£œé ãããã ãã®åå¿ã§ã¯è¯å¥œãªçµæã¯çœ®æã€ãœã·ã¢ããŒ
ããR1â眮æã¢ã·ã«ãããããµã é žã®ã¢ã«æ¿
床ã®ïŒåã®ã¢ã«æ¿åºŠã§ååšãããšãã«åŸãã
ããããã䜿çšåå¿äœã®éã¯èšççã§ã¯ãªãã
æãŸããçæç©ã®ãããã®ã¯åå¿äœãã©ããªå²
åã§çšãããããšãã«ãåŸãããã§ãããã åå¿äœãå¡©åã¡ãã¬ã³åã¯ããã©ããããã©
ã³ãªã©ã®äžæŽ»æ§ææ©æº¶åªäžã§ãžããã«é«ãžã©ãŠ
ã¬ãŒãåã¯ããªãšãã«ã¢ãã³ãªã©ã®å°éã®æŽ»æ§
åå€ã®ååšäžã§äºã«æ¥è§Šããããåå¿æ··åç©ã
çŽå®€æž©ã§å€§æ°å§äžã§å®è³ªçåå¿å®äºã確å®ã«
ãããããŠææçæç©ãåŸãã«ååãªæéæ¹æ
ããã®ãéœåè¯ããããé«ãå§ååã¯ããäœã
枩床ã䜿çšããåã¯åå¿ãå®äºãããããã«é«
å§ãçšããã®ãå¿ èŠãããããªãã åå¿ã®å®çµã«æŒãŠã溶åªãèžçºããéãåã¯
åŸæãªã©ã®æ £çšæè¡ã§åå¿æ··åç©ããé€å»ã
ããçæç©ã®ç²Ÿè£œã¯ãã®æè¡ã§è¯ãç¥ãããæ
é äŸãã°åçµæ¶ã§è¡ãã (B) ãã«ã«ããã«ã§R1ïŒR2åã³R3ãåã«äžã
ãæå³ãæããR2ãšR3ãç°ãªãéšåãè¡šãã
åŒã®ååç©ã¯å®è³ªçã«ïŒæ®µéæé ãçšããŠè£œ
é ãããã第ïŒæ®µéã§ã¯åŒã§è¡šããããã¢ã·
ã«ãããããµã é žããããçã¢ã«éã®ãåã«
R2ã«ã€ãå®çŸ©ããéšåã®äžã€ã§çœ®æãããã€
ãœã·ã¢ããŒããšåå¿ãããããã®åå¿ã®å®äºã«
æŒãŠãçæç©ããããçã¢ã«éã®ãR3ã«ã€ã
åã«å®çŸ©ããéšåã®äžã€ã§çœ®æãããã€ãœã·ã¢
ããŒããšåå¿ããææåŒååç©ãæ®ãã 䜿çšããåå¿äœã®æ£ç¢ºãªå²åã¯èšççã§ã¯ãª
ããããã®ïŒæ®µæ¹æ³ã®å段éã¯æ¬è³ªçã«çãã
å²åãè¡šããéã®åå¿äœãæ¶è²»ãããããŠãã®
æ§ãªéã®äœ¿çšã奜ãŸããã äžã®åå¿ãåã«äžèš(A)ã§èšãããšå®è³ªçã«å
ãåå¿æ¡ä»¶ã䜿çšããŠå®æœããã®ãéœåè¯ãã
ãããã®ååç©ã¯äžã®(A)ã«è¿°ã¹ãæ £çšæè¡ãçš
ããŠåååã³ç²Ÿè£œãè¡ãããã (C) ãã¹ã«ããã«ã§R1ïŒR2åã³R3ãåã«äžã
ãããæå³ãæããR2ãšãšR3ãåã眮æåºã§
ããåŒã®ååç©ã¯äžã®(A)ãšå®è³ªçã«åãæ¹æ³
ã§ãŸãå®è³ªçã«åãæ¡ä»¶åã³å²åã§è£œé ãã
ããåŒ ã®ææã®ïŒ®âããããã·âR1â眮æã¹ã«ãã¢
ããã¯çœ®æåºããåŒã®R2ãšR3ã®åã ã«å¯Ÿã
ãŠéžã°ãããã®ã§ãããããªã€ãœã·ã¢ããŒããš
åå¿ãããããã§çœ®æã€ãœã·ã¢ããŒãã®ã¢ã«æ¿
床ã¯åŒã®ïŒ®âããããã·âR1â眮æã¹ã«ã
ã¢ããã®ãã®ã®çŽïŒåã§ããã (D) åæ§ã«ïŒžãã¹ã«ããã«ã§R1ïŒR2åã³R3ãå
ã«äžããæå³ãæããR2ãšR3ãç°ãªãéšåã
è¡šããåŒã®ååç©ã¯äžã®(B)ã«èšãããã®ãšå®
質çã«åãæ¹æ³ã§ããããŠå®è³ªçã«åãæ¡ä»¶å
ã³å²åã§è£œé ããããåŒã®æãâãããã
ã·âR1â眮æã¹ã«ãã¢ããã¯R2ã«ã€ãåã«å®
矩ããéšåã®äžã€ã§çœ®æãããã€ãœã·ã¢ããŒã
ã®çŽçã¢ã«éãšåå¿ããããåå¿å®äºã«æŒãŠç
ããçæç©ãR3ã«ã€ãåã«å®çŸ©ããéšåã®äž
ã€ã§çœ®æãããçŽçã¢ã«éã®ã€ãœã·ã¢ããŒããš
åå¿ãããåŒã®æãååç©ãæ®ãã æ¬çºæååç©ã®è£œé ã«åºçºç©ãšããŠçšãããã
ååç©ã¯åœæè¡ã§ç¥ãããŠããã 次ã®å®æœäŸã¯æ¬çºæã説æããæ段ãšããŠèšã
ããããããã¯å¥œãŸããæ æ§ã®äŸã§ãã€ãŠæ¬çºæ
ãå¶éãããã®ãšããŠæå³ãããŠããªãã å®æœäŸ ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ã
ã ã¢ã»ããããããµã é žïŒ7.5ïœïŒãã¡ãã«ã€ãœã·
ã¢ããŒãïŒ12.0ã°ã©ã ïŒã80ããªãªããã«ïŒmlïŒ
ã®å¡©åã¡ãã¬ã³ãåã³çŽïŒæ»Žã®ããªãšãã«ã¢ãã³
ã®æ··åç©ã溶液ãåŸãããã«çŽïŒæéäžç·ã«æ¹æ
ããã溶液ã宀枩ã§äžå€æŸçœ®ãããã®åŸæº¶åªãç
空äžã«é€å»ããæ®æž£ãæ®ãããæ®æž£ãå¡©åã¡ãã¬
ã³ããåçµæ¶ããçœè²çµæ¶ãšããŠæãâïŒïŒã¡ã
ã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡ãã«ã¢ããïŒ
ã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãããæ®ãããè
ç¹ïŒm.p.ïŒ121ãã123.5âã å®æœäŸ ïŒ ïŒ®âïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒãš
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ã
ã ã¢ã»ããããããµã é žïŒ7.5ïœïŒããšãã«ã€ãœã·
ã¢ããŒãïŒ16.0ïœïŒåã³çŽïŒæ»Žã®ããªãšãã«ã¢ã
ã³ãçŽ50mlã®å¡©åã¡ãã¬ã³äžã§çŽ48æéæ¹æã
ããæ··åç©ã次ã«ç空äžã«æ¿çž®ãæ®æž£ãæ®ããã
ãã®æ®æž£ãå¡©åã¡ãã¬ã³ãšãããµã³ã®æº¶æ¶²ããïŒ
ååçµæ¶ããã次ã«å°éã®å¡©åã¡ãã¬ã³ããåçµ
æ¶ãããããã«ãšã³ããã®æçµã®åçµæ¶ã§çœè²çµ
æ¶ãšããŠæãâïŒïŒãšãã«ã¢ããïŒâã«ã«ããã«ïŒ
ââïŒïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒ
ã¢ã»ãã¢ãããçæãããèç¹84â86âã å®æœäŸ ïŒ ïŒ®âïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«
ã«ããã«ïŒââïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒ
ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãã ã¢ã»ããããããµã é žïŒ7.5ïœïŒã第ïŒããã«ã€
ãœã·ã¢ããŒãïŒ22ïœïŒåã³æ°æ»Žã®ããªãšãã«ã¢ã
ã³ã80mlã®å¡©åã¡ãã¬ã³äžã§çŽ48æéæ¹æããã
æ¹æåŸã溶åªãç空äžã«é€å»ããŠæ®æž£ãæ®ããã
ããå¡©åã¡ãã¬ã³åã³ãããµã³ãå«ã溶液ããå
çµæ¶ããããå¡©åã¡ãã¬ã³ããã®æ¬¡ã®åçµæ¶ã§æ
ãâïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«
ã«ããã«ïŒââïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒ
ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãããæ®
ã€ããèç¹111ãã113âã å®æœäŸ ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒããããªã³
ã¢ãã ããããªãããããµã é žïŒ4.5ïœïŒãã¡ãã«ã€ãœ
ã·ã¢ããŒãïŒ6.0ïœïŒåã³æ°æ»Žã®ããªãšãã«ã¢ã
ã³ãçŽïŒæéçŽ50mlã®å¡©åã¡ãã¬ã³äžã§æ¹æã
ããçãã溶液ã宀枩ã§çŽ48æéæŸçœ®ãããã®åŸ
溶åªãèžçºãããŠé€ãæ®æž£ãæ®ãããæ®æž£ãå¡©å
ã¡ãã¬ã³ãšãããµã³ã®æ··åç©ããåçµæ¶ããæã
âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡ã
ã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒããããªã³ã¢ã
ããçœè²çµæ¶ãšããŠæ®ã€ããèç¹90.5ã92.5âã å®æœäŸ ïŒ ïŒ®âïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒãš
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒããããªã³
ã¢ãã ããããªãããããµã é žïŒ4.5ïœïŒããšãã«ã€ãœ
ã·ã¢ããŒãïŒ8.0ïœïŒåã³æ°æ»Žã®ããªãšãã«ã¢ã
ã³ã100mlã®å¡©åã¡ãã¬ã³ã«å ãã宀枩ã§çŽ12æ
éæŸçœ®ããã溶åªã次ã«ç空äžã§é€ããæ®æž£ãæ®
ãããããå¡©åã¡ãã¬ã³ãšãããµã³ã®æº¶æ¶²ããå
çµæ¶ããçœè²çµæ¶ãšããŠæãâïŒïŒãšãã«ã¢ã
ãïŒã«ã«ããã«ïŒââïŒïŒïŒãšãã«ã¢ããïŒã«ã«ã
ãã«ïŒãªãã·ïŒããããªã³ã¢ãããæ®ãããèç¹
104âã106âã å®æœäŸ ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·âïŒïŒïŒâãž
ã¡ãã«ïŒããããªã³ã¢ãã ïŒïŒïŒïŒâãžã¡ãã«ïŒããããªãããããµã é ž
ïŒ5.9ïœïŒãã¡ãã«ã€ãœã·ã¢ããŒãïŒ6.5ïœïŒåã³æ°
滎ã®ããªãšãã«ã¢ãã³ãçŽ50mlã®å¡©åã¡ãã¬ã³äž
ã§çŽ48æéæ¹æããããã®æ··åç©ã次ã«ç空äžã§
æ¿çž®ããç¡è²ã®æ²¹ç¶æ®æž£ãæ®ããããã®æ²¹ããã
ãµã³ãšããç ããšç²çæ§ã®åºäœãæ®ãããããå¡©
åã¡ãã¬ã³ãšãããµã³ã®æº¶æ¶²ããåçµæ¶ãããã
ãã®åŸã®æå°éã®å¡©åã¡ãã¬ã³åã³ãã«ãšã³ãã
ã®åçµæ¶ã§çœè²çµæ¶ãšããŠæãâïŒïŒã¡ãã«ã¢ã
ãïŒâã«ã«ããã«ïŒââïŒïŒïŒã¡ãã«ã¢ããïŒã«ã«
ããã«ïŒãªãã·ïŒïŒïŒïŒïŒâãžã¡ãã«ïŒããããª
ã³ã¢ãããæ®ã€ããèç¹117ãã119âïŒçŽ116âã
ããããã®çŒçµããïŒã äžèšã®æé ãšå®è³ªçã«åæé ã§é©åœãªçœ®æã¢ã·
ã«ãããããµã é žãé©åœãªã€ãœã·ã¢ããŒããšåå¿
ãããããšã«ãã次ã®ååç©ãã€ãã€ãã å®æœäŸïŒïŒ âïŒïŒã·ã¯ãããã·ã«ã¢ããïŒã«ã«
ããã«ïŒââïŒïŒïŒã·ã¯ãããã·ã«ã¢ããïŒã«ã«
ããã«ïŒãªãã·ïŒã¢ã»ãã¢ããèç¹109ãã112
âã å®æœäŸïŒïŒ âïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢ããïŒ
ã«ã«ããã«ïŒââïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢ã
ãïŒã«ã«ããã«ïŒãªãã·ã¢ã»ãã¢ããèç¹65ã
ã68âã å®æœäŸïŒïŒ âïŒïŒãããã«ã¢ããïŒã«ã«ãã
ã«ïŒââïŒïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒãª
ãã·ïŒã¢ã»ãã¢ãããèç¹50ãã53âã å®æœäŸ10ïŒ ïŒ®âïŒïŒããšãã«ã¢ããïŒã«ã«ãã
ã«ïŒââïŒïŒïŒããšãã«ã¢ããïŒã«ã«ããã«ïŒãª
ãã·ïŒã¢ã»ãã¢ãããèç¹134ãã136âã å®æœäŸ11ïŒ ïŒ®âïŒïŒïŒïŒâã¡ãã«ããšãã«ïŒã¢ã
ãïŒã«ã«ããã«ïŒââïŒïŒïŒïŒïŒâã¡ãã«ããšã
ã«ïŒã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ã
ã å®æœäŸ12ïŒ ïŒ®âïŒïŒïŒïŒâã¡ãã«ããšãã«ïŒã¢ã
ãïŒã«ã«ããã«ïŒââïŒïŒïŒïŒïŒâã¡ãã«ããšã
ã«ïŒã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ã
ããèç¹140ãã142âã å®æœäŸ13ïŒ ïŒ®âïŒïŒããã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒããã«ã¢ããïŒâã«ã«ããã«ïŒãªã
ã·ïŒã¢ã»ãã¢ãã å®æœäŸ14ïŒ ïŒ®âïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢ããïŒ
ã«ã«ããã«ïŒââïŒïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢
ããïŒã«ã«ããã«ïŒãªãã·ïŒãã³ãºã¢ãã å®æœäŸ15ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒã¡ãã«ã¢ããïŒâã«ã«ããã«ïŒãªã
ã·ïŒãã³ãºã¢ãããèç¹131ãã133âã å®æœäŸ16ïŒ ïŒ®âïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒ
ãã³ãºã¢ãããèç¹154ãã155âã å®æœäŸ17ïŒ ïŒ®âïŒïŒãããã«ã¢ããïŒã«ã«ãã
ã«ïŒââïŒïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒãª
ãã·ïŒãã³ãºã¢ããèç¹66ãã69âã å®æœäŸ18ïŒ ïŒ®âïŒïŒããã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒããã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒ
ãã³ãºã¢ããèç¹42ã43âã å®æœäŸ19ïŒ ïŒ®âïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒ
ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒïŒïŒïŒïŒâãžã¡
ãã«ãšãã«ïŒã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã
ã³ãºã¢ããèç¹133ãã134âã å®æœäŸ20ïŒ ïŒ®âïŒïŒããšãã«ã¢ããïŒã«ã«ãã
ã«ïŒââïŒïŒïŒããšãã«ã¢ããïŒã«ã«ããã«ïŒãª
ãã·ïŒãã³ãºã¢ãã å®æœäŸ21ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒ
ã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãã (a) âïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ã
ãïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãã ã¢ã»ããããããµã é žïŒ7.5ïœïŒã第ïŒããã«ã€
ãœã·ã¢ããŒãïŒ10.0ïœïŒåã³æ°æ»Žã®ããªãšãã«ã¢
ãã³ã宀枩ã§çŽ200mlã®å¡©åã¡ãã¬ã³äžã§ïŒæé
æ¹æããããã®æéã®åŸãåå¿ããã®äžæº¶åºäœã
æ¿ŸéããŠéãææçæç©ã§ããããšã決å®ããã
ã液ãç空äžã«æ¿çž®ããŠæ®æž£ãæ®ããããããã«
ãšã³ããåçµæ¶ãããè¿œå éã®ææã®ïŒ®â
ïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«ã«ãã
ã«ïŒãªãã·ïŒã¢ã»ãã¢ãããæ®ããã (b) âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââ
ïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«ã«
ããã«ïŒãªãã·ïŒã¢ã»ãã¢ãã âïŒïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«
ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ããïŒ8.7ïœïŒãã¡ã
ã«ã€ãœã·ã¢ããŒãïŒ3.2ïœïŒåã³æ°æ»Žã®ããªãšã
ã«ã¢ãã³ã宀枩ã§150mlã®å¡©åã¡ãã¬ã³äžã§çŽ12
æéæ¹æããã溶åªã次ã«ç空äžã§é€ãæ²¹ç¶æ®æž£
ãæ®ãããããç±ããã«ãšã³äžã«æº¶è§£ãããå·åŽ
ãããšçœè²ã®çµæ¶ç©è³ªãåé¢ããæ¿Ÿéã§éããã
çœè²ã®çµæ¶ããã«ãšã³ããåçµæ¶ãããæ®æž£ãæ®
ãããããçŽ50mlã®æ°ŽãšçŽïŒæéæ··åãããæ··å
ç©ã次ã«æ¿Ÿéãã次ã«äžæº¶ç©ãç空也ç¥ããæã
âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒïŒïŒ
ïŒ
ïŒâãžã¡ãã«ãšãã«ïŒã¢ããïŒã«ã«ããã«ïŒãªã
ã·ïŒã¢ã»ãã¢ãããèç¹142ã144âãæ®ããã å®æœäŸ 22 âïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒââ
ïŒïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã·
ã¯ããããã³ã«ã«ãããµãã (a) âããããã·ã·ã¯ããããã³ã«ã«ãããµã
ãã®è£œé çŽ500mlã®ã¡ã¿ããŒã«äžã®çŽ1.3ã¢ã«ã®ãããã
ã·ã«ã¢ãã³å¡©é žå¡©ã®æº¶æ¶²ã調補ããŠå·åŽãããã
ãã«çŽ2.0ã¢ã«ã®æ°Žé žåã«ãªãŠã ãå«æãã300ml
ã®ã¡ã¿ããŒã«æº¶æ¶²ãå ãããçŽïŒååŸããšãã«ã·
ã¯ããããã³ã«ã«ããã·ã¬ãŒãïŒ0.66ã¢ã«ïŒãå
ããããã®åå¿æ··åç©ãçŽ10ååŸã«æ¿ŸéããŠãæ®
枣ãæ®ãããããã¡ã¿ããŒã«ã§æŽã€ãåŸã«é žæ§ã«
ãããé žæ§ã«ããæ··åç©ããéããã液ãæ¿çž®ã
ãŠåºäœãæ®ãããåºäœãé ¢é žãšãã«ããåçµæ¶ã
ããçœè²åºäœãæ®ããâããããã·ã·ã¯ããã
ãã³ã«ã«ãããµããã§ããããšã決å®ãããèç¹
117ã119â (b) âïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒââ
ïŒïŒïŒãããã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã·
ã¯ããããã³ã«ã«ãããµãã âããããã·ã·ã¯ããããã³ã«ã«ãããµãã
ïŒ5.0ïœïŒãïœâãããã«ã€ãœã·ã¢ããŒãïŒ9.3ïœïŒ
åã³ïŒæ»Žã®ããªãšãã«ã¢ãã³ã宀枩ã§çŽ100mlã®
å¡©åã¡ãã¬ã³äžã§çŽ12æéæ¹æãããåå¿æ··åç©
ã次ã«æ¿çž®ããŠæ²¹ç¶æ®çç©ãæ®ããããã²ã€ãã
ãšçµæ¶åããããã®åºäœã次ã«ã·ã¯ããããµã³ãš
ã€ãœãããããŒã«ã®æ··åç©ããåçµæ¶ãããããŠ
也ç¥ãããã也ç¥ãããšæãâïŒïŒãããã«ã¢ã
ãïŒã«ã«ããã«ïŒââïŒïŒïŒãããã«ã¢ããïŒã«ã«
ããã«ïŒãªãã·ïŒã·ã¯ããããã³ã«ã«ãããµãã
ãçœè²åºäœãšããŠåŸããããèç¹76ãã78â å®è³ªçã«åãæé ã䜿ã€ãŠæ¬¡ã®ååç©ãã€ãã€
ãã å®æœäŸ 23 âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã·ã¯ããã
ãã³ã«ã«ãããµãããèç¹109ãã111â å®æœäŸ24 âïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒâ
âïŒïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒ
ã·ã¯ããããã³ã«ã«ãããµããèç¹120ã122
âã å®æœäŸ25 âïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢ããïŒ
ã«ã«ããã«ïŒââïŒïŒïŒïŒïŒâã¡ãã«ãšãã«ïŒã¢
ããïŒã«ã«ããã«ïŒãªãã·ïŒã·ã¯ããããã³ã«
ã«ãããµããèç¹99ãã101âã å®æœäŸ26 âïŒïŒããã«ã¢ããïŒã«ã«ããã«ïŒâ
âïŒïŒïŒããã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒ
ã·ã¯ããããã³ã«ã«ãããµãããèç¹48ãã49
âã å®æœäŸ27 âïŒïŒïŒïŒïŒïŒâãžã¡ãã«ãšãã«ïŒã¢
ããïŒã«ã«ããã«ïŒââïŒïŒïŒïŒïŒïŒïŒâãžã¡ã
ã«ãšãã«ïŒã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã·ã¯
ããããã³ã«ã«ãããµããã å®æœäŸ28 âïŒïŒããšãã«ã¢ããïŒã«ã«ããã«ïŒ
ââïŒïŒïŒããšãã«ã¢ããïŒã«ã«ããã«ïŒãªã
ã·ïŒã·ã¯ããããã³ã«ã«ãããµãããèç¹140
ã142âã å®æœäŸ29 âïŒïŒã·ã¯ãããã·ã«ã¢ããïŒã«ã«ã
ãã«ïŒââïŒïŒïŒã·ã¯ãããã·ã«ã¢ããïŒã«ã«ã
ãã«ïŒãªãã·ïŒã·ã¯ããããã³ã«ã«ãããµã
ããèç¹122ãã124âã å®æœäŸ 30 âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¡ã¿ã³ã¹ã«
ãã¢ãã (a) âããããã·ã¡ã¿ã³ã¹ã«ãã¢ããã®è£œé ãããªãŠã ã¡ããã·ãã®æº¶æ¶²ã23ïœã®ãããªãŠ
ã ã300mlã®ã¡ã¿ããŒã«äžã«æº¶ãããŠã€ãã€ãã
ãã®æº¶æ¶²ã300mlã®ã¡ã¿ããŒã«äžã®69ïœã®ããã
ãã·ã«ã¢ãã³å¡©é žå¡©ã«ïŒå·åŽããªããïŒå ãã次
ã«æ¿Ÿéãããã液ãçŽ15âã«å·ãããã¡ã¿ã³ã¹ã«
ããã«ã¯ãã©ã€ãïŒ19.3mlïŒãçŽ48æéåŸå ãã
åå¿æ··åç©ããéããã液ãæ¿çž®ããŠæ®æž£ãæ®ã
ããæ®æž£ããžãšãã«ãšãŒãã«ã§ïŒåæœåºããäžç·
ã«ãããšãŒãã«æœåºç©ãæ¿çž®ããŠæããé»è²ã®ç²
æ§ã®æ²¹ãæ®ãããçœè²ã®åºäœãã²ã€ãããåŸã«åœ¢
æãããããã¯æãâããããã·ã¡ã¿ã³ã¹ã«ã
ã¢ãããšäžèŽããèµ€å€åžåãæããŠããã (b) âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââ
ïŒïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¡ã¿
ã³ã¹ã«ãã¢ãã âããããã·ã¡ã¿ã³ã¹ã«ãã¢ããïŒ8.0ïœïŒã
ã¡ãã«ã€ãœã·ã¢ããŒãïŒ9.4mlïŒåã³çŽïŒæ»Žã®ã
ãªãšãã«ã¢ãã³ãçŽ80mlã®å¡©åã¡ãã¬ã³äžã§æ¥è§Š
ãããåå¿ãé²è¡ããã«åŸãçœè²åºäœã圢æã
ãã次ã«ååãããåºäœãã€ãœãããããŒã«ãã
åçµæ¶ããæãâïŒïŒã¡ãã«ã¢ããïŒã«ã«ãã
ã«ïŒââïŒïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒãªã
ã·ïŒã¡ã¿ã³ã¹ã«ãã¢ãããæ®ãããèç¹131ãã
132â æ¬è³ªçã«å®æœäŸ30ãšåãæé ã«åŸã€ãŠæ¬¡ã®åå
ç©ãã€ãã€ãã å®æœäŸ 31 âïŒïŒãšãã«ã¢ããïŒã«ã«ããã«ïŒââïŒïŒïŒãš
ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¡ã¿ã³ã¹ã«
ãã¢ãã åŒã®ååç©ã®ç©æ§ã¯è¡šïŒã«èšãããã
ãè¡šã
ãè¡šã
ãè¡šã
ãè¡šã
â
O
O
â
31 CHïŒ CïŒHïŒ
CïŒHïŒ âSâ
â
O
å®æœäŸ 32 æ¬çºæã®ååç©ã¯ãã©çŽ°èïŒé ã®äººã®çïŒã®çŽ°
èæé·ãé»æ¢ããå¹åã瀺ãããã®æŽ»æ§ã¯æ¬¡ã®æ
é ã䜿ã€ãŠå®èšŒãããã ãã©çŽ°èããïŒmlã®çè²å¹å°ïŒEagleã®æå°å¿
é å¹å°ã®ïŒïŒ HIFCSãæãããã®ïŒäžãŠãšã«åœ
ã30现èã®æ¿åºŠã§24ã®ãŠãšã«æ°ã®çµç¹å¹é€ãã¬ãŒ
ãäžã«æ€ããããã¬ãŒãïŒå¹³æ¿å¹å°ïŒã¯36âã§24
æéå¹é€ããåŸçè²å¹å°ãé€ããã现èãïŒmlã®
äžèšã®æ°ããªçè²å¹å°äžã«æž¬å®ããéïŒïŒã50
mgïŒmlïŒã®æ¬çºæååç©ã®äžã€ãšå ±ã«åæžæ¿ã
ããïŒmgïŒmlã®æ¿åºŠã¯å¯Ÿç §ãšããŠåœ¹ç«ãŠããçµç¹
å¹é€ãã¬ãŒãã次ã«36âã§ïŒæ¥å¹é€ãããã®æç¹
ã§å¹å°ãé€ã现èãåºå®ããŠ20ïŒ ãšã¿ããŒã«äžã®
0.1ïŒ ã¯ãªã¹ã¿ã«ãã€ãªã¬ããã§æããããã©çŽ°
èã®éèœã¯èçŒã§æ°ããåŠçãŠãšã«ãšå¯Ÿç §ãŠãšã«
ã®ã³ãããŒå¯žæ³ã®æ¯èŒãè¡ããè©Šéšååç©ã¯å¯Ÿç §
ãšæ¯ã¹ãŠ50ïŒ åã¯ãã以äžãã©çŽ°èã³ãããŒã®æ°
ãæžããæ¿åºŠã§çŽ°èæ¯ãšèãããæ¬çºæã®è©Šéšå
åç©ã¯å¯Ÿç §ãšæ¯ã¹æž¬å®ã§ããéã ãã³ãããŒã®å¯ž
æ³ãæžå°ãããæ¿åºŠã§ãã©çŽ°èã®çè²ãé»æ¢ãã
ãšèããããã®è©Šéšã®çµæã¯æ¬¡ã®è¡šïŒã«èšãã
â
O
O
â
31 CHïŒ CïŒHïŒ
CïŒHïŒ âSâ
â
O
å®æœäŸ 32 æ¬çºæã®ååç©ã¯ãã©çŽ°èïŒé ã®äººã®çïŒã®çŽ°
èæé·ãé»æ¢ããå¹åã瀺ãããã®æŽ»æ§ã¯æ¬¡ã®æ
é ã䜿ã€ãŠå®èšŒãããã ãã©çŽ°èããïŒmlã®çè²å¹å°ïŒEagleã®æå°å¿
é å¹å°ã®ïŒïŒ HIFCSãæãããã®ïŒäžãŠãšã«åœ
ã30现èã®æ¿åºŠã§24ã®ãŠãšã«æ°ã®çµç¹å¹é€ãã¬ãŒ
ãäžã«æ€ããããã¬ãŒãïŒå¹³æ¿å¹å°ïŒã¯36âã§24
æéå¹é€ããåŸçè²å¹å°ãé€ããã现èãïŒmlã®
äžèšã®æ°ããªçè²å¹å°äžã«æž¬å®ããéïŒïŒã50
mgïŒmlïŒã®æ¬çºæååç©ã®äžã€ãšå ±ã«åæžæ¿ã
ããïŒmgïŒmlã®æ¿åºŠã¯å¯Ÿç §ãšããŠåœ¹ç«ãŠããçµç¹
å¹é€ãã¬ãŒãã次ã«36âã§ïŒæ¥å¹é€ãããã®æç¹
ã§å¹å°ãé€ã现èãåºå®ããŠ20ïŒ ãšã¿ããŒã«äžã®
0.1ïŒ ã¯ãªã¹ã¿ã«ãã€ãªã¬ããã§æããããã©çŽ°
èã®éèœã¯èçŒã§æ°ããåŠçãŠãšã«ãšå¯Ÿç §ãŠãšã«
ã®ã³ãããŒå¯žæ³ã®æ¯èŒãè¡ããè©Šéšååç©ã¯å¯Ÿç §
ãšæ¯ã¹ãŠ50ïŒ åã¯ãã以äžãã©çŽ°èã³ãããŒã®æ°
ãæžããæ¿åºŠã§çŽ°èæ¯ãšèãããæ¬çºæã®è©Šéšå
åç©ã¯å¯Ÿç §ãšæ¯ã¹æž¬å®ã§ããéã ãã³ãããŒã®å¯ž
æ³ãæžå°ãããæ¿åºŠã§ãã©çŽ°èã®çè²ãé»æ¢ãã
ãšèããããã®è©Šéšã®çµæã¯æ¬¡ã®è¡šïŒã«èšãã
ãè¡šã
ãè¡šã
å®æœäŸ 33
åŒã®ååç©ã¯ããçš®ã®åºä¹³é¡ã®è
«çã®æ²»çã
ç¹ã«P388çœè¡ç åã³ïŒåã¯MXâïŒçã®æ²»çã«æ
çšã§ããã æ¬ååç©é¡ã®æ°çç©ç 掻æ§ã¯æ¬¡ã®è©Šéšæé ã䜿
ã€ãŠå®èšŒããã (A) å®éšçšããŠã¹ïŒCDF1ããŠã¹ïŒã«è ¹è å ã«106
ã®P388ãªã³ãççœè¡ç ã®çŽ°èãå«æããè ¹æ°Žæ¶²
ã泚å°ãããè©Šéšååç©ã¯é©åœãªæäžéã§å¡©æ°Ž
âãã€ãŒã³80æ äœäžã®ãã®ãšããŠè ¹è å ã«æ¯æ¥
ïŒæ¥éæäžããæåã®åŠçœ®ã¯è «çæ¥è§ŠåŸç¬¬ïŒæ¥
ã«è¡ã€ããå¯Ÿç §ããŠã¹ã¯ååç©ãäœãåããªã
ã€ããåŠçœ®åã³æªåŠçœ®ïŒå¯Ÿç §ïŒããŠã¹ã®çåæ
éãèªããçµæ㯠åŠçœ®çŸ€ã®äžéçåæéïŒå¯Ÿç §äžéçåæéÃ100 ãå¯Ÿç §çåæéã®ããŒã»ã³ããšããŠè¡šãã
ïŒïŒŽïŒïŒ£ïŒãåŸã€ãŠã100ãã倧ããå€ã¯å¯Ÿç §çŸ€
ãšæ¯èŒããŠåŠçœ®çŸ€ã®äžéçåæéãå¢å ããã
ãšã瀺ããŠããã
ç¹ã«P388çœè¡ç åã³ïŒåã¯MXâïŒçã®æ²»çã«æ
çšã§ããã æ¬ååç©é¡ã®æ°çç©ç 掻æ§ã¯æ¬¡ã®è©Šéšæé ã䜿
ã€ãŠå®èšŒããã (A) å®éšçšããŠã¹ïŒCDF1ããŠã¹ïŒã«è ¹è å ã«106
ã®P388ãªã³ãççœè¡ç ã®çŽ°èãå«æããè ¹æ°Žæ¶²
ã泚å°ãããè©Šéšååç©ã¯é©åœãªæäžéã§å¡©æ°Ž
âãã€ãŒã³80æ äœäžã®ãã®ãšããŠè ¹è å ã«æ¯æ¥
ïŒæ¥éæäžããæåã®åŠçœ®ã¯è «çæ¥è§ŠåŸç¬¬ïŒæ¥
ã«è¡ã€ããå¯Ÿç §ããŠã¹ã¯ååç©ãäœãåããªã
ã€ããåŠçœ®åã³æªåŠçœ®ïŒå¯Ÿç §ïŒããŠã¹ã®çåæ
éãèªããçµæ㯠åŠçœ®çŸ€ã®äžéçåæéïŒå¯Ÿç §äžéçåæéÃ100 ãå¯Ÿç §çåæéã®ããŒã»ã³ããšããŠè¡šãã
ïŒïŒŽïŒïŒ£ïŒãåŸã€ãŠã100ãã倧ããå€ã¯å¯Ÿç §çŸ€
ãšæ¯èŒããŠåŠçœ®çŸ€ã®äžéçåæéãå¢å ããã
ãšã瀺ããŠããã
ãè¡šã
è¡šïŒã«è¡šãããããŒã¿ãŒã¯ïŒ®âïŒïŒïŒã¡ãã«ã¢
ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡ãã«ã¢ããïŒã«
ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ããïŒååç©ïŒã¯
P388çœè¡ç ã«ããã€ãè©ŠéšããŠã¹ã®äžéçåæ
éãå¢å ããããšã瀺ããŠããã ãã®ååç©ã¯è©Šéšåç©ã®äžéçåæéãäžã€
ã®å®éšã§æ³šå°åœãäœéããã°ã©ã åœã50ããªã°
ã©ã ïŒ50mgïŒKgïŒã®æäžéã§ããŸãå¥ã®å®éšã§
12.50ïŒ25ïŒåã³50mgïŒKgã®æäžéã§å¢å ããã
ä»ã®ç¹ã§ã¯äžæŽ»æ§ã®è©Šéšã§ãéå°ã®æ»äº¡åã¯é
å°ã®äœéæ倱ãæ¯æ§æ¥ã«ã¿ãããã®ã¯çåã¢ã
ã«ã«æŒããæ¯æ§åã¯è «çé»æ¢ã¢ãã«ã§ã®åœæŽ»æ§
ã瀺ããã®ã§ããã (B) ïŒãš12ã®éã®æ¥çŒãã€ã¯ãã¡ãŒã¿ãŒåäœ
ïŒOMOïŒïŒãããïŒÃïŒÃïŒããªã¡ãŒã¿ãŒïŒã®
çŽåŸãæããè «ççïŒMXâïŒäººã®èžãã»ãã°
ã©ããïŒã移æ€ãããã®å Žã§ç¡èžè ºã¹ã€ã¹
ïŒNuïŒNuã¹ã€ã¹ïŒããŠã¹ã®è äžã®ã«ãã»ã«äž
ã§æž¬å®ãããå¡©æ°Žæ äœäžã®è©Šéšååç©ã®é©åœæ
äžéãïŒæ¥ïŒå10æ¥éç®äžæ³šå°ãããæåã®åŠ
眮ã¯è «ç移æ€åŸç¬¬ïŒæ¥ã«è¡ã€ããå¯Ÿç §ããŠã¹ã«
ã¯è©Šéšååç©ãæäžããªãã€ããè©ŠéšããŠã¹ã
11æ¥ç®ã«æ®ºããŠè «ç寞æ³ãèªãããè «çåŸã®å¯Ÿ
ç §ã®è «ç寞æ³ãšæ¯èŒããå€åïŒç§»æ€æ¥ã®ïŒæ¥ç®
ãã殺ããæ¥ã®11æ¥ç®ïŒãè «ççé·åã¯éè¡ã®
è©äŸ¡ãšããŠäœ¿çšããã
ããïŒã«ã«ããã«ïŒââïŒïŒïŒã¡ãã«ã¢ããïŒã«
ã«ããã«ïŒãªãã·ïŒã¢ã»ãã¢ããïŒååç©ïŒã¯
P388çœè¡ç ã«ããã€ãè©ŠéšããŠã¹ã®äžéçåæ
éãå¢å ããããšã瀺ããŠããã ãã®ååç©ã¯è©Šéšåç©ã®äžéçåæéãäžã€
ã®å®éšã§æ³šå°åœãäœéããã°ã©ã åœã50ããªã°
ã©ã ïŒ50mgïŒKgïŒã®æäžéã§ããŸãå¥ã®å®éšã§
12.50ïŒ25ïŒåã³50mgïŒKgã®æäžéã§å¢å ããã
ä»ã®ç¹ã§ã¯äžæŽ»æ§ã®è©Šéšã§ãéå°ã®æ»äº¡åã¯é
å°ã®äœéæ倱ãæ¯æ§æ¥ã«ã¿ãããã®ã¯çåã¢ã
ã«ã«æŒããæ¯æ§åã¯è «çé»æ¢ã¢ãã«ã§ã®åœæŽ»æ§
ã瀺ããã®ã§ããã (B) ïŒãš12ã®éã®æ¥çŒãã€ã¯ãã¡ãŒã¿ãŒåäœ
ïŒOMOïŒïŒãããïŒÃïŒÃïŒããªã¡ãŒã¿ãŒïŒã®
çŽåŸãæããè «ççïŒMXâïŒäººã®èžãã»ãã°
ã©ããïŒã移æ€ãããã®å Žã§ç¡èžè ºã¹ã€ã¹
ïŒNuïŒNuã¹ã€ã¹ïŒããŠã¹ã®è äžã®ã«ãã»ã«äž
ã§æž¬å®ãããå¡©æ°Žæ äœäžã®è©Šéšååç©ã®é©åœæ
äžéãïŒæ¥ïŒå10æ¥éç®äžæ³šå°ãããæåã®åŠ
眮ã¯è «ç移æ€åŸç¬¬ïŒæ¥ã«è¡ã€ããå¯Ÿç §ããŠã¹ã«
ã¯è©Šéšååç©ãæäžããªãã€ããè©ŠéšããŠã¹ã
11æ¥ç®ã«æ®ºããŠè «ç寞æ³ãèªãããè «çåŸã®å¯Ÿ
ç §ã®è «ç寞æ³ãšæ¯èŒããå€åïŒç§»æ€æ¥ã®ïŒæ¥ç®
ãã殺ããæ¥ã®11æ¥ç®ïŒãè «ççé·åã¯éè¡ã®
è©äŸ¡ãšããŠäœ¿çšããã
ãè¡šã
ãè¡šã
è¡šïŒã«ç€ºãããçµæã¯æ¬çºæã®ååç©ãå®è³ªç
ãªæäžç¯å²ã«ãããMXâïŒçã«å¯ŸããŠåªãã掻
æ§ã瀺ãããšããããããŠããããããã®ååç©
ã§ã®åŠçœ®ã¯è «çã®æé·é床ãé ãããã ãã§ãª
ããããå Žåã«ã¯ååç©ã¯è «ç寞æ³ãæžå°ãã
ãã ååç©ã¯åºä¹³é¡ã«éçµå£çãäŸãã°è ¹è å ãç®
äžåã¯éèå 泚å°ã«ããæäžåºæ¥ããå éšæäžã®
çµè·¯ã¯æå¹ãªææ°çç©éã®ååç©ïŒå³ã¡çè²é»æ¢
éã®ååç©ïŒãè «çã«æ¥è§Šããããšã確å®ã«ãã
ããã«éžã°ããã¹ãã§ããã æ¬çºææ¹æ³ãå®æœããã®ã«äœ¿çšãããååç©ã®
æ£ç¢ºãªéãå³ã¡æãè «ççè²é»æ¢å¹æãäžããã«
ååãªååç©ã®éã¯ã䜿çšã®ååç©ãæ¥è§Šåã¯æ
äžã®ååŒãåºä¹³é¡ã®å¯žæ³ã幎什åã³çš®ãæäžã®çµ
è·¯ãæéãé »åºŠãåã³é¢äžããæ°çç©ãã®æ§ãª
çš®ã ã®å åã«äŸåãããåã ã®å Žåã«æŒãŠæäžã
ããã¹ãéã¯æ £çšã®ç¯å²çºèŠæè¡ã«ãã決å®åºæ¥
ãã ååç©ã¯åŒã«å¯Ÿå¿ããïŒåã¯ãã以äžã®åå
ç©ã«ã補è¬äžåãå ¥ããããæ äœãå³ã¡æŽ»æ§åå
ç©ã«ååŠçã«äžæŽ»æ§ã§äœ¿çšæ¡ä»¶äžã«æªãå¯äœçšå
ã¯æ¯æ§ãæããªãæ äœäŸãã°å¡©æ°Žåã¯çºç±è³ªã®ãª
ãæ°Žãæ··åãããã®ãããªãçµæç©ã®åœ¢åŒã§ãå
éšçåã¯å±æçã«æäžããã®ã奜ãŸããã çµæç©ã¯æ» èãã泚å°å¯èœãªæžæ¿æ¶²åã¯æº¶æ¶²ãª
ã©ã®æ¶²äœåœ¢ã§ããã補è¬äžåãå ¥ããããæ äœã¯
è¡šé¢æŽ»æ§èª¿åå€åã³æžæ¿å€ãªã©ã®è³Šåœ¢è¬ãå«ã¿åŸ
ããé©åœãªè³Šåœ¢è¬ã¯äŸãã°ã¬ãã³ãã³ãº ãã¢ãŒ
ãã¹âãã€ã«ã« ãããŠãã¢ã¯ãã€ãªã³ã°ç¬¬13
çãããŒã¯ ãããªãã·ã³ã° ã«ã³ãããŒããã³
ã·ã«ãã㢠ãšã¹ãã³ïŒ1965ïŒãªã©ã®ããã¹ãã«
é瀺ãããŠããã
ãªæäžç¯å²ã«ãããMXâïŒçã«å¯ŸããŠåªãã掻
æ§ã瀺ãããšããããããŠããããããã®ååç©
ã§ã®åŠçœ®ã¯è «çã®æé·é床ãé ãããã ãã§ãª
ããããå Žåã«ã¯ååç©ã¯è «ç寞æ³ãæžå°ãã
ãã ååç©ã¯åºä¹³é¡ã«éçµå£çãäŸãã°è ¹è å ãç®
äžåã¯éèå 泚å°ã«ããæäžåºæ¥ããå éšæäžã®
çµè·¯ã¯æå¹ãªææ°çç©éã®ååç©ïŒå³ã¡çè²é»æ¢
éã®ååç©ïŒãè «çã«æ¥è§Šããããšã確å®ã«ãã
ããã«éžã°ããã¹ãã§ããã æ¬çºææ¹æ³ãå®æœããã®ã«äœ¿çšãããååç©ã®
æ£ç¢ºãªéãå³ã¡æãè «ççè²é»æ¢å¹æãäžããã«
ååãªååç©ã®éã¯ã䜿çšã®ååç©ãæ¥è§Šåã¯æ
äžã®ååŒãåºä¹³é¡ã®å¯žæ³ã幎什åã³çš®ãæäžã®çµ
è·¯ãæéãé »åºŠãåã³é¢äžããæ°çç©ãã®æ§ãª
çš®ã ã®å åã«äŸåãããåã ã®å Žåã«æŒãŠæäžã
ããã¹ãéã¯æ £çšã®ç¯å²çºèŠæè¡ã«ãã決å®åºæ¥
ãã ååç©ã¯åŒã«å¯Ÿå¿ããïŒåã¯ãã以äžã®åå
ç©ã«ã補è¬äžåãå ¥ããããæ äœãå³ã¡æŽ»æ§åå
ç©ã«ååŠçã«äžæŽ»æ§ã§äœ¿çšæ¡ä»¶äžã«æªãå¯äœçšå
ã¯æ¯æ§ãæããªãæ äœäŸãã°å¡©æ°Žåã¯çºç±è³ªã®ãª
ãæ°Žãæ··åãããã®ãããªãçµæç©ã®åœ¢åŒã§ãå
éšçåã¯å±æçã«æäžããã®ã奜ãŸããã çµæç©ã¯æ» èãã泚å°å¯èœãªæžæ¿æ¶²åã¯æº¶æ¶²ãª
ã©ã®æ¶²äœåœ¢ã§ããã補è¬äžåãå ¥ããããæ äœã¯
è¡šé¢æŽ»æ§èª¿åå€åã³æžæ¿å€ãªã©ã®è³Šåœ¢è¬ãå«ã¿åŸ
ããé©åœãªè³Šåœ¢è¬ã¯äŸãã°ã¬ãã³ãã³ãº ãã¢ãŒ
ãã¹âãã€ã«ã« ãããŠãã¢ã¯ãã€ãªã³ã°ç¬¬13
çãããŒã¯ ãããªãã·ã³ã° ã«ã³ãããŒããã³
ã·ã«ãã㢠ãšã¹ãã³ïŒ1965ïŒãªã©ã®ããã¹ãã«
é瀺ãããŠããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ åŒ ïŒåŒäžR1ïŒR2åã³R3ã¯åã ç¬ç«ã«æ°ŽçŽ ãççŽ
ååïŒãïŒåã®ã¢ã«ãã«ãççŽ ååïŒãïŒåã®ã·
ã¯ãã¢ã«ãã«ãããšãã«ãççŽ ååïŒãïŒåã®ã¢
ã«ãã«åºïŒãïŒåã§çœ®æãããããšãã«ãè¡šãã
ã¯ã«ã«ããã«åã¯ã¹ã«ããã«ãè¡šãïŒã«å¯Ÿå¿ã
ãååç©ã ïŒ ïŒžãã«ã«ããã«ã§ãã第ïŒé ã«å®çŸ©ã®åå
ç©ã ïŒ R1ïŒR2åã³R3ã¯åã ã¢ã«ãã«ã§ãã第ïŒé
ã«å®çŸ©ã®ååç©ã ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââ
ïŒïŒïŒã¡ãã«ã¢ããïŒâã«ã«ããã«ïŒâãªãã·ïŒã¢ã»
ãã¢ããã§ãã第ïŒé ã®ååç©ã ïŒ åŒ ïŒåŒäžR1ïŒR2åã³R3ã¯åã ç¬ç«ããŠãççŽ å
åïŒãïŒåã®ã¢ã«ãã«ãã¯ã«ã«ããã«ãè¡šãïŒ
ã«å¯Ÿå¿ããååç©ã®P388çœè¡ç åã¯MXâïŒçã®
æè²ãé»æ¢ããã«æå¹ãªéãšè£œè¬äžåãå ¥ããã
ãæ äœãšãçµåãããã®ãããªãP388çœè¡ç å
ã¯MXâïŒçã®æè²ãé»æ¢ããã«æçšãªçµæç©ã ïŒ ïŒ®âïŒïŒã¡ãã«ã¢ããïŒã«ã«ããã«ïŒââ
ïŒïŒïŒã¡ãã«ã¢ããïŒâã«ã«ããã«ïŒâãªãã·ïŒã¢ã»
ãã¢ããã§ãã第ïŒé ã®çµæç©ã ïŒ (a) R2ãšR3ïŒR2ãšR3ã¯äžã«å®çŸ©ãããéãïŒ
ãåãã§ããååç©ã«ã€ããŠã¯R1ââ
NHOHïŒR1ã¯äžã«å®çŸ©ã®éãïŒã®åŒã®ååç©
ã®ïŒã¢ã«å²åãåŒR2âïŒïŒ£ïŒïŒ¯ã®ã€ãœã·ã¢
ããŒãã®ïŒã¢ã«å²åãšåå¿ããã (b) R2ãšR3ãäºã«ç°ãªãååç©ã«ã€ããŠã¯ããŸ
ãïŒã¢ã«å²åã®åŒR1ââNHOHã®ååç©ã
ïŒã¢ã«å²åã®åŒR2âïŒïŒ£ïŒïŒ¯ã®ã€ãœã·ã¢ã
ãŒããšåå¿ããã第ïŒã®æ®µéã§ïŒã¢ã«å²åã®ç°
ãªãåŒR3âïŒïŒ£ïŒïŒ¯ã®ã€ãœã·ã¢ããŒããšç¬¬
ïŒæ®µéã®çæç©ãšãåå¿ããããããã®åå¿ã®
ãã¹ãŠãäžæŽ»æ§ã®ææ©æº¶åªäžã§ã觊åªéã®æŽ»æ§
åå€ã®ååšäžã§çŽïŒâã60âã®æž©åºŠã§è¡ãªãå
å¿ãããªããåŒ ã®ååç©ã®è£œæ³ ïŒäžåŒäžR1ãR2åã³R3ã¯ç¬ç«ããŠæ°ŽçŽ ãäœ
çŽã¢ã«ãã«ãã·ã¯ãã¢ã«ãã«ãããšãã«åã¯äœ
çŽã¢ã«ãã«çœ®æããšãã«ããç¬ç«ããŠéžã°ãã
ã¯ãåŒãåã¯ãåŒããè¡šãïŒã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US349502 | 1982-02-17 | ||
US06/349,502 US4413009A (en) | 1982-02-17 | 1982-02-17 | N-((Alkylamino)carbonyl)-N-(((alkylamino)carbonyl)oxy)acylamides with antineoplastic activity |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS58152858A JPS58152858A (ja) | 1983-09-10 |
JPH0359898B2 true JPH0359898B2 (ja) | 1991-09-12 |
Family
ID=23372667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58022245A Granted JPS58152858A (ja) | 1982-02-17 | 1983-02-15 | ææ°çç©æŽ»æ§ãæããïŒïœâïŒïŒã¢ã«ãã«ã¢ããïŒã«ã«ããã«ïŒâïœâïŒïŒã¢ã«ãã«ã¢ããïŒã«ã«ããã«ïŒãªãã·ïŒã¢ã·ã«ã¢ããé¡ |
Country Status (13)
Country | Link |
---|---|
US (1) | US4413009A (ja) |
EP (1) | EP0086492B1 (ja) |
JP (1) | JPS58152858A (ja) |
AT (2) | AT387962B (ja) |
BE (1) | BE895923A (ja) |
CA (1) | CA1196007A (ja) |
CH (1) | CH653014A5 (ja) |
DE (2) | DE3305107A1 (ja) |
FR (1) | FR2521555A1 (ja) |
GB (1) | GB2115414B (ja) |
IT (1) | IT1199988B (ja) |
NL (1) | NL8300598A (ja) |
SE (1) | SE8300854L (ja) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3786088A (en) * | 1968-12-05 | 1974-01-15 | Velsicol Chemical Corp | N,o-dicarbamoyl-n-phenylhydroxylamines |
US3836572A (en) * | 1973-04-02 | 1974-09-17 | Monsanto Co | Dicarbamoyl hydroxamates |
US4030912A (en) * | 1973-04-11 | 1977-06-21 | Hercules Incorporated | Certain oximinyl allophanates and their use as herbicides |
US3957867A (en) * | 1973-04-11 | 1976-05-18 | Hercules Incorporated | Certain oximinyl allophanates and their use as herbicides |
US4207091A (en) * | 1976-02-09 | 1980-06-10 | Ciba-Geigy Corporation | Method of preventing plants from damage by frost |
-
1982
- 1982-02-17 US US06/349,502 patent/US4413009A/en not_active Expired - Lifetime
-
1983
- 1983-02-14 CA CA000421553A patent/CA1196007A/en not_active Expired
- 1983-02-14 CH CH811/83A patent/CH653014A5/de not_active IP Right Cessation
- 1983-02-14 AT AT0049483A patent/AT387962B/de not_active IP Right Cessation
- 1983-02-15 DE DE19833305107 patent/DE3305107A1/de not_active Withdrawn
- 1983-02-15 GB GB08304146A patent/GB2115414B/en not_active Expired
- 1983-02-15 AT AT83101435T patent/ATE22071T1/de not_active IP Right Cessation
- 1983-02-15 JP JP58022245A patent/JPS58152858A/ja active Granted
- 1983-02-15 EP EP83101435A patent/EP0086492B1/en not_active Expired
- 1983-02-15 DE DE8383101435T patent/DE3365949D1/de not_active Expired
- 1983-02-16 IT IT19608/83A patent/IT1199988B/it active
- 1983-02-16 SE SE8300854A patent/SE8300854L/xx not_active Application Discontinuation
- 1983-02-16 BE BE0/210127A patent/BE895923A/fr not_active IP Right Cessation
- 1983-02-17 NL NL8300598A patent/NL8300598A/nl not_active Application Discontinuation
- 1983-02-17 FR FR8302605A patent/FR2521555A1/fr active Granted
Also Published As
Publication number | Publication date |
---|---|
US4413009A (en) | 1983-11-01 |
AT387962B (de) | 1989-04-10 |
SE8300854L (sv) | 1983-08-18 |
EP0086492A3 (en) | 1984-06-06 |
GB8304146D0 (en) | 1983-03-16 |
FR2521555A1 (fr) | 1983-08-19 |
DE3365949D1 (en) | 1986-10-16 |
GB2115414B (en) | 1985-09-18 |
FR2521555B1 (ja) | 1985-05-17 |
DE3305107A1 (de) | 1983-08-18 |
IT8319608A1 (it) | 1984-08-16 |
EP0086492B1 (en) | 1986-09-10 |
BE895923A (fr) | 1983-08-16 |
ATE22071T1 (de) | 1986-09-15 |
CH653014A5 (de) | 1985-12-13 |
EP0086492A2 (en) | 1983-08-24 |
NL8300598A (nl) | 1983-09-16 |
CA1196007A (en) | 1985-10-29 |
IT1199988B (it) | 1989-01-05 |
SE8300854D0 (sv) | 1983-02-16 |
GB2115414A (en) | 1983-09-07 |
JPS58152858A (ja) | 1983-09-10 |
IT8319608A0 (it) | 1983-02-16 |
ATA49483A (de) | 1988-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6583165B2 (en) | Arylsulfonanilide ureas | |
US3679698A (en) | 2-nitroimidazoles | |
KR870000741B1 (ko) | ë²€ì ì€í° ì믞ë ì ë첎ì ì ì¡° ë°©ë² | |
EP0242851A1 (de) | N-(2'-Aminophenyl)-benzamid-Derivate, Verfahren zu deren Herstellung und deren Verwendung bei der BekÀmpfung neoplastischer Erkrankungen | |
EP0525111B1 (en) | Antiinflammatory hydroxamic acids and n-hydroxyureas | |
FR2555181A1 (fr) | Nouveaux derives de la carboxymethoxy-7 furo-(3,4-c)-pyridine ainsi que leur procede de preparation | |
DE69108408T2 (de) | 4,5-dihydroxy und 4,5,8-trihydroxy-9,10-dioxo-2-anthracencarbonsÀure-dikohlensÀureester und urethane mit therapeutischer wirkung. | |
JP3009196B2 (ja) | æãŠã€ã«ã¹æŽ»æ§ãæããè¬å€ãçè質èªå°äœåã³ãã®è£œé æ¹æ³ | |
FR2580642A1 (fr) | 5-pyrimidinecarboxamides et traitement de la leucemie et des tumeurs en les utilisant | |
US2945877A (en) | Carbamic acid esters of 2, 4, 5-trichlorophenol | |
FI61886C (fi) | Foerfarande foer framstaellning av i tumoerterapi anvaendbara 1-alkylkarbamoyl-5-fluoruraciler | |
US2449638A (en) | Substituted glycinamides | |
JPH0359898B2 (ja) | ||
DE69402142T2 (de) | Ornithine-decarboxylase hemmende cyclische aminooxy-verbindungen | |
PL128998B1 (en) | Process for preparing novel 2-amino-3-benzoylphenylacetamides and their derivatives | |
US2829084A (en) | Certain alkyl-n | |
GB2024814A (en) | Acyl (bicyclic aryl) - aminoalkanoic acids | |
US3929803A (en) | Aryl carboxylic acids | |
Elslager et al. | Synthetic schistosomicides. XVI. 5-(Mono-and dialkylamino)-2-nitrosophenols, 2-amino-5-(dialkylamino) phenols, and related compounds | |
WO1998031688A1 (fr) | Derives d'acides boroniques inhibiteurs d'angiogenese | |
US3850931A (en) | 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters | |
CA1138866A (en) | Chemical process for preparing isoxazolo-benzoxazinone derivatives | |
US3299089A (en) | Derivatives of 5-methyloxazoline and 5-chloromethyloxazoline | |
AU685980B2 (en) | Inhibition of leukotriene biosynthesis with urea derivatives | |
EP0172059B1 (fr) | Nouveaux dérivés de l'oxaazaphosphorine, leur procédé de préparation et les compositions pharmaceutiques les renfermant |